

USE OF CUCURBITACINS AND WITHANOLIDES FOR THE TREATMENT OF CANCER

SUMMARY

The National Cancer Institute's Laboratory of Experimental Immunology, Cancer Inflammation Program, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the use of certain cucurbitacins or withanolides in combination with pro-apoptotic agonists of TRAIL death receptors for cancer therapy.

REFERENCE NUMBER

E-050-2010

PRODUCT TYPE

- Therapeutics

KEYWORDS

- mapatumamab
- TRAIL
- immunotherapy
- cucurbitacin
- withanolide

COLLABORATION OPPORTUNITY

This invention is available for licensing.

CONTACT

John D. Hewes
NCI - National Cancer Institute
240-276-5515

John.Hewes@nih.gov

DESCRIPTION OF TECHNOLOGY

Certain members of the cucurbitacin and Withanolide family have been identified that can sensitize some tumor cell lines to cell death (apoptosis) on subsequent exposure of the cells to pro-apoptotic receptor agonists (PARAS) of the TRAIL "death receptors". These PARAS include TRAIL itself, and agonist antibodies to two of its receptors death receptor-4 (DR4 or TRAIL-R1) and death receptor 5 (DR5, TRAIL-R2).

The protein TRAIL has a very interesting characteristic that it can preferentially cause death of cancer cells whereas normal non-transformed cells are unaffected. Thus use of TRAIL or agonist antibodies to its so-called "death receptors" has been a current focus in cancer therapy.

POTENTIAL COMMERCIAL APPLICATIONS

- Use of the compounds with known TRAIL or agonist antibodies such as Mapatumumab or in combination with immunotherapeutic approaches for the treatment of cancer.

COMPETITIVE ADVANTAGES

- Cucurbitacins and withanolides can be successfully developed in combination with known TRAIL agonist have the potential of new cancer combination therapies without major toxicities.

INVENTOR(S)

Thomas J Sayers (NCI)

DEVELOPMENT STAGE

- Pre-clinical (in vivo)

PUBLICATIONS

- NL Booth et al. A cell-based high-throughput screen to identify synergistic TRAIL sensitizers. *Cancer Immunol Immunother.* 2009 Aug;58(8):1229-1244. [PubMed: 19089423]

PATENT STATUS

- **U.S. Filed:** U.S. Provisional Application No. 61/287,139 filed 16 Dec 2009

THERAPEUTIC AREA

- Cancer/Neoplasm